Tumour metabolism: Translating the undruggable target

Nature Reviews Cancer 16, 675 (2016). doi:10.1038/nrc.2016.107 Author: Anna Dart Three studies demonstrate the preclinical potential of a novel class of hypoxia-inducible factor 2α (HIF2α) antagonists in the treatment of von Hippel–Lindau (pVHL)-deficient clear cell renal cell carcinoma.
Source: Nature Reviews Cancer - Category: Cancer & Oncology Authors: Tags: Research Highlight Source Type: research